Terheyden, Jan Henrik http://orcid.org/0000-0002-0174-4066
Ost, Reglind A. D.
Behning, Charlotte
Mekschrat, Liza
Bildik, Gamze
Wintergerst, Maximilian W. M. http://orcid.org/0000-0002-2766-7038
Holz, Frank G.
Finger, Robert P. http://orcid.org/0000-0003-4253-7597
Funding for this research was provided by:
Universitätsklinikum Bonn
Article History
Received: 14 June 2023
Revised: 3 November 2023
Accepted: 30 November 2023
First Online: 5 January 2024
Declarations
:
: Ethical approval was obtained from the Institutional Review Board of the University Hospital Bonn (reference number: 130/16). The study protocol followed the principles of the Declaration of Helsinki.
: Written informed consent was obtained from all participants of the study.
: Not applicable.
: JHT: Heidelberg Engineering, Optos, Zeiss, CenterVue, Novartis, Okko; RADO: Heidelberg Engineering, Optos, Zeiss, CenterVue; CB: none; LM: Heidelberg Engineering, Optos, Zeiss, CenterVue; GB: Heidelberg Engineering, Optos, Zeiss, CenterVue; MWMW: Heidelberg Engineering (F, R), Optos (F), Carl Zeiss Meditec (F), CenterVue (F), Heine Optotechnik GmbH (C, R, F), Berlin-Chemie AG (F), Novartis Pharma GmbH (R, F), D-Eye Srl (F), Eyenuk Inc. (F), ASKIN & CO GmbH (R), DigiSight Technologies (R); FGH: Acucela, Allergan, Apellis, Bayer, Boehringer-Ingelheim, Bioeq/Formycon, CenterVue, Ellex, Roche/Genentech, Geuder, Grayburg Vision, Heidelberg Engineering, Kanghong, LinBioscience, NightStarX, Novartis, Optos, Pixium Vision, Oxurion, Stealth BioTherapeutics, Zeiss; RPF: Bayer, Ellex, Novartis, Novartis, Opthea, Alimera, Santhera, Roche/Genentech, CentreVue, Zeiss.